Wider window for stroke drug

Stroke patients can benefit from treatment with alteplase even if they miss the drug's three-hour treatment window, research suggests.

But fast treatment remains patients' best hope of achieving recovery, researchers stressed.

The thrombolytic drug alteplase is currently licensed for use within three hours of an acute ischaemic stroke.

Researchers from the University of Heidelberg, Germany, looked at benefits for patients outside this window.

They randomised 821 patients presenting between three and 4.5 hours after onset of stroke to receive alteplase or placebo.

All endpoints studied showed benefits for a wide range of patients, but not all differences were statistically significant.

'Our results support the use of this thrombolytic drug in the extended period across a broad range of patient subgroups,' the researchers said.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Whitehall street sign

NHS officials doubled in two years as GP workforce dropped

Staff employed by NHS England and the DHSC doubled in two years from the start of...

Child coughing

NICE traffic light tool that helps GPs spot seriously ill under-5s 'unreliable'

NICE's 'traffic light' system - intended to help GPs identify risk of serious illness...

Pregnant woman receives COVID-19 vaccine

COVID-19 vaccine uptake in pregnant women rising but stark inequality remains

More than half of pregnant women are now double vaccinated against COVID-19 as uptake...

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

GMC sign

Overseas-graduate GPs fare worse in medical tribunals due to lack of legal help

UK GPs who graduated overseas face worse outcomes in GMC cases because they are far...

Woman using HRT patch

Practical advice for GPs on prescribing HRT

GP menopause specialists Dr Louise Newson and Dr Olivia Jones provides an overview...